News

ETD001, Enterprise Therapeutics’ inhaled investigational therapy to improve mucus clearance in people with cystic fibrosis (CF) — regardless of the underlying CF-causing mutation — was well tolerated in healthy individuals at doses higher than those predicted to be therapeutic, a study showed. The now-complete Phase 1…

Biomx is ending a Phase 2b trial of BX004, its investigational nebulized phage therapy for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF). The move comes on the heels of a safety review of the trial (NCT06998043) conducted by an independent data monitoring committee, which…

After starting treatment with Trikafta, people with cystic fibrosis (CF) tend to have less need for inhaled mucus-clearing therapies and antibiotics, according to a new analysis of data from a real-world study. Moreover, the reduced need for other medication while on Trikafta was found to continue over the…

An independent data monitoring committee, following a safety review, recommended that a Phase 2 trial of BX004, Biomx’s experimental treatment for Pseudomonas aeruginosa infection in people with cystic fibrosis (CF), continue with revised dosing. Although Europe’s part of the study is advancing, the U.S. Food and Drug Administration (FDA)…

Adults with cystic fibrosis (CF) who are not eligible for Kaftrio therapy reported feeling forgotten in both the media and research, with conflicting emotions about those who do benefit from the approved treatment, according to a new interview-based study by researchers in the U.K. Study participants noted that…

People with cystic fibrosis (CF) who have certain lung structure abnormalities — ones visible on CT scans — are more likely than those with other issues also seen via imaging to experience improvements in lung function after starting treatment with Trikafta. That’s according to the results of a new analysis…

The U.S. Food and Drug Administration (FDA) has cleared the start of the third part of a Phase 2 clinical trial testing RCT2100, Recode Therapeutics’ investigational treatment for cystic fibrosis (CF). This portion of the Phase 2 trial (NCT06237335) will test RCT2100 together with Kalydeco (ivacaftor) in…

Six months of treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) helped open the nasal and sinus passages in people with cystic fibrosis (CF), a study reports. For many people with CF, these passages — which make up the sinonasal cavity — often become inflamed or develop growths and infections. Treatment with…

The U.S. approval of CFTR modulators for cystic fibrosis (CF) may have reduced or delayed the need for liver transplants among people in the country with CF-related liver disease, or CFrLD, a new study suggests. Since the U.S. Food and Drug Administration (FDA) approved Trikafta (elexacaftor/tezacaftor/ivacaftor) — the first…

Researchers in Italy have developed a new experimental compound called 3b, which has shown early promise as a dual-action therapy for cystic fibrosis (CF). It addresses the dysfunction of the CFTR protein that causes the disease, as well as protects against viral threats that can worsen lung problems. In…